Login to Your Account



Clinic Roundup


Wednesday, April 11, 2012
• Omeros Corp., of Seattle, said it started patient enrollment in its second Phase III trial of PharmacoSurgery candidate OMS302 in intraocular lens replacement (ILR) surgery. The product is designed to be added to standard irrigation solution used during ILR procedures to maintain intraoperative mydriasis and reduce postoperative pain. About 400 patients undergoing cataract surgery or refractive lens exchange will be recruited, with data expected later this year. In the first Phase III study, the product hit statistical significance, showing superiority over placebo on both endpoints (p < 0.00001).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription